Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Molgramostim inhalation for autoimmune pulmonary alveolar proteinosis. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Molgramostim inhalation is a new drug to treat autoimmune pulmonary alveolar proteinosis (PAP). Autoimmune PAP is a rare lung disease that causes a build-up of protein material in the air sacs of the lungs, making it difficult to breath. Molgramostim inhalation is breathed in and works by altering the body's immune response, helping to prevent the build-up of protein in the lungs. Indexing Status Subject indexing assigned by CRD MeSH Administration, Inhalation; Autoimmune Diseases; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Pulmonary Alveolar Proteinosis Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016001037 Date abstract record published 11/10/2016 |